Hydromer Reports 14% Revenue Growth Amid Strategic Investments

Hydromer, Inc., a pioneer in medical device coating technologies, has announced its preliminary, unaudited financial results for the second quarter of 2025, showcasing a 14% revenue increase to $0.94 million from the previous year. Despite a net loss of $38,000 attributed to legal and professional expenses, the company emphasizes its strategic investments in innovation and market expansion as key drivers for future growth. CEO Michael E. Torti highlights the resilience of Hydromer's core business and its commitment to advancing its product pipeline and forming new partnerships. With over four decades of expertise, Hydromer continues to lead in providing hydrophilic, thromboresistant, and antimicrobial coating solutions, adhering to global standards like ISO 9001:2015 and GMP. The company's forward-looking statements caution investors about potential uncertainties but reaffirm its dedication to innovation and operational efficiency.